Physician profile
Jamilla C Stone
NPI 1932337029
$2,329.49
in general payments reported to CMS, 2019-2025
18 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $333 · 2023: $600 · 2024: $606 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $525.21 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $267.02 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $255.40 | 2022-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $240.78 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $219.51 | 2023-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $208.82 | 2022-2025 | |
| Exact Sciences Corporation | $108.72 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.07 | 2022-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $106.04 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $62.12 | 2022-2023 | Rexulti, Abilify Maintena |
| Amgen INC. | $60.61 | 2023-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $53.35 | 2023-2025 | |
| Axsome Therapeutics, INC. | $25.20 | 2025 | Symbravo |
| Dexcom, INC. | $22.53 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $20.16 | 2023 | Accrufer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $16.36 | 2024 | Leqembi |
| Medtronic, INC. | $16.08 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.51 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamilla Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.